NASDAQ:PTIX Protagenic Therapeutics (PTIX) Stock Price, News & Analysis $0.70 -0.03 (-4.10%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.70▼$0.7350-Day Range$0.70▼$1.8052-Week Range$0.68▼$2.22Volume5,469 shsAverage Volume6,530 shsMarket Capitalization$3.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Protagenic Therapeutics alerts: Email Address Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Protagenic Therapeutics Stock (NASDAQ:PTIX)Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.Read More PTIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTIX Stock News HeadlinesMay 22, 2024 | finance.yahoo.comProtagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric DisordersApril 17, 2024 | finanznachrichten.deProtagenic Therapeutics, Inc.: Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston SummitJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.April 17, 2024 | finance.yahoo.comProtagenic Therapeutics’ Innovative Peptide PT00114 to be Highlighted at Boston SummitApril 2, 2024 | msn.comProtagenic Therapeutics, Inc. (NASDAQ:PTIX) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finance.yahoo.comProtagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric DisordersMarch 25, 2024 | finanznachrichten.deProtagenic Therapeutics, Inc.: Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings CallFebruary 13, 2024 | finance.yahoo.comProtagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related DisordersJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.December 17, 2023 | morningstar.comProtagenic Therapeutics Inc PTIXNovember 14, 2023 | seekingalpha.comPTIX Protagenic Therapeutics, Inc.October 13, 2023 | finanznachrichten.deProtagenic Therapeutics, Inc.: Protagenic Therapeutics Announces Date of Annual Shareholder MeetingOctober 13, 2023 | finance.yahoo.comProtagenic Therapeutics Announces Date of Annual Shareholder MeetingSeptember 26, 2023 | finanznachrichten.deProtagenic Therapeutics, Inc.: Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114September 26, 2023 | finance.yahoo.comProtagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114June 17, 2023 | uk.finance.yahoo.comPTIX - Protagenic Therapeutics, Inc.March 24, 2023 | benzinga.comProtagenic Therapeutics Stock (NASDAQ:PTIX), DividendsMarch 22, 2023 | finanznachrichten.deProtagenic Therapeutics, Inc.: Protagenic Therapeutics to Effect 1-for-4 Reverse Stock SplitSee More Headlines Receive PTIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagenic Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTIX CUSIPN/A CIK1022899 Webwww.protagenic.com Phone212-994-8200Fax603-761-6223Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,000,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-156.36% Return on Assets-124.79% Debt Debt-to-Equity RatioN/A Current Ratio5.53 Quick Ratio5.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.83 per share Price / Book0.84Miscellaneous Outstanding Shares4,450,000Free Float2,805,000Market Cap$3.12 million OptionableNot Optionable Beta0.27 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Garo H. Armen Ph.D. (Age 71)Co-Founder & Executive Chairman of the Board Dr. Alexander Kenneth Arrow C.F.A. (Age 53)M.D., CFO & Secretary Comp: $150kDr. Andrew Slee (Age 74)Chief Operating Officer Dr. Robert Benjamin Stein M.D. (Age 73)Ph.D., Chief Medical Officer & Director Key CompetitorsKiora PharmaceuticalsNASDAQ:KPRXImunonNASDAQ:IMNNCardio DiagnosticsNASDAQ:CDIOEterna TherapeuticsNASDAQ:ERNAPHAXIAM TherapeuticsNASDAQ:PHXMView All CompetitorsInsidersAlexander K ArrowBought 8,000 shares on 10/12/2023Total: $6,480.00 ($0.81/share)View All Insider Transactions PTIX Stock Analysis - Frequently Asked Questions How have PTIX shares performed this year? Protagenic Therapeutics' stock was trading at $0.99 on January 1st, 2024. Since then, PTIX shares have decreased by 29.2% and is now trading at $0.7013. View the best growth stocks for 2024 here. How were Protagenic Therapeutics' earnings last quarter? Protagenic Therapeutics, Inc. (NASDAQ:PTIX) announced its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.39) earnings per share for the quarter. How do I buy shares of Protagenic Therapeutics? Shares of PTIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PTIX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagenic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagenic Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.